Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives
Emanuele D’Amico, Aurora Zanghì, Matteo Gastaldi, et al.
Autoimmunity Reviews (2019) Vol. 18, Iss. 7, pp. 665-672
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

The role of TH17 cells in multiple sclerosis: Therapeutic implications
Tobias Moser, Katja Akgün, Undine Proschmann, et al.
Autoimmunity Reviews (2020) Vol. 19, Iss. 10, pp. 102647-102647
Closed Access | Times Cited: 212
Digital Twins for Multiple Sclerosis
Isabel Voigt, Hernán Inojosa, Anja Dillenseger, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 193
Clinical outcome measures in multiple sclerosis: A review
Hernán Inojosa, Dirk Schriefer, Tjalf Ziemssen
Autoimmunity Reviews (2020) Vol. 19, Iss. 5, pp. 102512-102512
Closed Access | Times Cited: 138
Transitional B cells involved in autoimmunity and their impact on neuroimmunological diseases
Yang Zhou, Ying Zhang, Jinming Han, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 83
Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk
Austin P. Passaro, Abraham L. Lebos, Yao Yao, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 76
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis
Emanuele D’Amico, Aurora Zanghì, Alessandra Romano, et al.
Cells (2019) Vol. 8, Iss. 10, pp. 1114-1114
Open Access | Times Cited: 57
Immunological consequences of “immune reconstitution therapy” in multiple sclerosis: A systematic review
Johann Sellner, Paulus Rommer
Autoimmunity Reviews (2020) Vol. 19, Iss. 4, pp. 102492-102492
Closed Access | Times Cited: 43
FGF/FGFR Pathways in Multiple Sclerosis and in Its Disease Models
R. Rajendran, Gregor Böttiger, Christine Stadelmann, et al.
Cells (2021) Vol. 10, Iss. 4, pp. 884-884
Open Access | Times Cited: 40
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study
Aurora Zanghì, Antonio Gallo, Carlo Avolio, et al.
Neurotherapeutics (2021) Vol. 18, Iss. 2, pp. 1166-1174
Open Access | Times Cited: 33
Identifying Cladribine prescription pattern in MS: an Italian multicentre study
Aurora Zanghì, Roberta Fantozzi, Matteo Foschi, et al.
Therapeutic Advances in Neurological Disorders (2025) Vol. 18
Open Access
Role of B cells and antibodies in multiple sclerosis
Pitchaya Wanleenuwat, Piotr Iwanowski
Multiple Sclerosis and Related Disorders (2019) Vol. 36, pp. 101416-101416
Closed Access | Times Cited: 32
Mental health status of relapsing-remitting multiple sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: A monocentric experience
Aurora Zanghì, Emanuele D’Amico, Maria Luca, et al.
Multiple Sclerosis and Related Disorders (2020) Vol. 46, pp. 102561-102561
Open Access | Times Cited: 30
Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD
Sara Esmaeili, Mohammad Hossein Abbasi, Meysam Abolmaali, et al.
BMC Neurology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 24
Ocrelizumab Extended Interval Dosing in Primary Progressive Multiple Sclerosis: An Italian Experience
Aurora Zanghì, Diana Ferraro, Graziella Callari, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 2, pp. 339-345
Open Access | Times Cited: 9
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
Aurora Zanghì, Giovanna Borriello, Simona Bonavita, et al.
Journal of Neurology (2024) Vol. 271, Iss. 7, pp. 4495-4502
Open Access | Times Cited: 3
Global burden of multiple sclerosis and its attributable risk factors, 1990–2019
Saeid Safiri, Amir Ghaffari Jolfayi, Seyed Ehsan Mousavi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Personality Traits and Fatigue in Multiple Sclerosis: A Narrative Review
Alessia Ciancio, Maria Claudia Moretti, Antimo Natale, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4518-4518
Open Access | Times Cited: 9
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis
Emanuele D’Amico, Aurora Zanghì, Nunziatina Laura Parrinello, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
A new perspective on therapies involving B-cell depletion in autoimmune diseases
Sulieman Ibraheem Shelash Al-Hawary, Saade Abdalkareem Jasim, Ahmed Hjazi, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 2
Experience with rituximab therapy in a real-life sample of multiple sclerosis patients
Angelo Bellinvia, Elio Prestipino, Emilio Portaccio, et al.
Neurological Sciences (2020) Vol. 41, Iss. 10, pp. 2939-2945
Closed Access | Times Cited: 14
Corticosteroid-depending effects on peripheral immune cell subsets vary according to disease modifying strategies in multiple sclerosis
Lena Höpner, Undine Proschmann, Hernán Inojosa, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system
Cristina Scavone, Antonietta Anatriello, Isabella Baccari, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 1
Diagnosis dan Tatalaksana Ensefalitis Autoimun Antibodi Negatif
Dewi Ramadani Hosen, Osmond Muftilov Pison
Jurnal Anestesi Perioperatif (2024) Vol. 12, Iss. 2, pp. 153-160
Open Access | Times Cited: 1
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
Carrie M. Hersh, Magdaliz Gorritz, Chi‐Chang Chen, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 91, pp. 105888-105888
Open Access | Times Cited: 1
Complete Freund's adjuvant-free experimental autoimmune encephalomyelitis in Dark Agouti rats is a valuable tool for multiple sclerosis studies
Milica Lazarević, Neda Djedović, Suzana Stanisavljević, et al.
Journal of Neuroimmunology (2021) Vol. 354, pp. 577547-577547
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top